Sargramostim Clinical Trials

Infectious Disease

COVID-19

Sargramostim Use in COVID-19 to Recover Patient Health (SCOPE)

Study of Sargramostim in Patients With COVID-19 (iLeukPulm)

Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)

Using GM-CSF as a Host Directed Therapeutic Against COVID-19

A Phase II/III Study of Sargramostim in Patients With Coronavirus Disease-2019 (COVID-19) (Japan)

Cancer

Hematologic Malignancies

GM-CSF With Post-Transplant Cyclophosphamide

Solid Tumors

Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors (SALIENT)

Melanoma

Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Biliary Cancer

Pembrolizumab and GM-CSF in Biliary Cancer

Lung Cancer

Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advanced Non-small Cell Lung Cancer

Neurology

Parkinson’s disease

Biomarker Assessments of Leukine During Treatment of Parkinson’s Disease

Alzheimer’s Disease

Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer’s Disease

Vascular

Peripheral Arterial Disease

Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease (GPAD-3)

 

Note: Not all clinical trials including sargramostim are listed.